Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Journal of clinical oncology

Results: 51-75/4838

Authors: Del Mastro, L Venturini, M Lionetto, R Carnino, F Guarneri, D Gallo, L Contu, A Pronzato, P Vesentini, L Bergaglio, M Comis, S Rosso, R
Citation: L. Del Mastro et al., Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: Resultsof a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group, J CL ONCOL, 19(8), 2001, pp. 2213-2221

Authors: Grasselli, G Vigano, L Capri, G Locatelli, A Tarenzi, E Spreafico, C Bertuzzi, A Giani, A Materazzo, C Cresta, S Perotti, A Valagussa, P Gianni, L
Citation: G. Grasselli et al., Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer, J CL ONCOL, 19(8), 2001, pp. 2222-2231

Authors: Fountzilas, G Papadimitriou, C Dafni, U Bafaloukos, D Skarlos, D Moulopouos, LA Razis, E Kalofonos, HP Aravantinos, G Briassoulis, E Papakostas, P Abela, K Gogas, E Kosmidis, P Pavlidis, N Dimopoulos, MA
Citation: G. Fountzilas et al., Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the Hellenic Cooperative Oncology Group, J CL ONCOL, 19(8), 2001, pp. 2232-2239

Authors: Buchholz, TA Tucker, SL Erwin, J Mathur, D Strom, EA McNeese, MD Hortobagyi, GN Cristofanilli, M Esteva, FJ Newman, L Singletary, SE Buzdar, AU Hunt, KK
Citation: Ta. Buchholz et al., Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy, J CL ONCOL, 19(8), 2001, pp. 2240-2246

Authors: Martin, AM Blackwood, MA Antin-Ozerkis, D Shih, HA Calzone, K Colligon, TA Seal, S Collins, N Stratton, MR Weber, BL Nathanson, KL
Citation: Am. Martin et al., Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic, J CL ONCOL, 19(8), 2001, pp. 2247-2253

Authors: Morrow, M White, J Moughan, J Owen, J Pajack, T Sylvester, J Wilson, JF Winchester, D
Citation: M. Morrow et al., Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma, J CL ONCOL, 19(8), 2001, pp. 2254-2262

Authors: Bijker, N Peterse, JL Duchateau, L Julien, JP Fentiman, IS Duval, C Di Palma, S Simony-Lafontaine, J de Mascarel, I van de Vijver, MJ
Citation: N. Bijker et al., Risk factors for recurrence and metastasis after breast-conserving therapyfor ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853, J CL ONCOL, 19(8), 2001, pp. 2263-2271

Authors: Sturm, I Petrowsky, H Volz, R Lorenz, M Radetzki, S Hillebrand, T Wolff, G Hauptmann, S Dorken, B Daniel, PT
Citation: I. Sturm et al., Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: High BAX and p16(nk4a/CDKN2) identifies patients with good prognosis, J CL ONCOL, 19(8), 2001, pp. 2272-2281

Authors: Hoff, PM Ansari, R Batist, G Cox, J Kocha, W Kuperminc, M Maroun, J Walde, D Weaver, C Harrison, E Burger, HU Osterwalder, B Wang, AO Wong, R
Citation: Pm. Hoff et al., Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study, J CL ONCOL, 19(8), 2001, pp. 2282-2292

Authors: Evans, WE Hon, YY Bomgaars, L Coutre, S Holdsworth, M Janco, R Kalwinsky, D Keller, F Khatib, Z Margolin, J Murray, J Quinn, J Ravindranath, Y Ritchey, K Roberts, W Rogers, ZR Schiff, D Steuber, C Tucci, F Kornegay, N Krynetski, EY Relling, MV
Citation: We. Evans et al., Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine, J CL ONCOL, 19(8), 2001, pp. 2293-2301

Authors: Palmer, SL Goloubeva, O Reddick, WE Glass, JO Gajjar, A Kun, L Merchant, TE Mulhern, RK
Citation: Sl. Palmer et al., Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis, J CL ONCOL, 19(8), 2001, pp. 2302-2308

Authors: Dowlati, A Hoppel, CL Ingalls, ST Majka, S Li, XL Sedransk, N Spiro, T Gerson, SL Ivy, P Remick, SC
Citation: A. Dowlati et al., Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days, J CL ONCOL, 19(8), 2001, pp. 2309-2318

Authors: Sausville, EA Arbuck, SG Messmann, R Headlee, D Bauer, KS Lush, RM Murgo, A Figg, WD Lahusen, T Jaken, S Jing, XX Roberge, M Fuse, E Kuwabara, T Senderowicz, AM
Citation: Ea. Sausville et al., Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms, J CL ONCOL, 19(8), 2001, pp. 2319-2333

Authors: Yamauchi, H Stearns, V Hayes, DF
Citation: H. Yamauchi et al., When is a tumor marker ready for prime time? A case study of c-erbB-2 as apredictive factor in breast cancer, J CL ONCOL, 19(8), 2001, pp. 2334-2356

Authors: Col, NF Hirota, LK Orr, RK Erban, JK Wong, JB Lau, J
Citation: Nf. Col et al., Hormone replacement therapy after breast cancer: A systematic review and quantitative assessment of risk, J CL ONCOL, 19(8), 2001, pp. 2357-2363

Authors: Piver, MS
Citation: Ms. Piver, Surgery in advanced epithelial ovarian cancer, J CL ONCOL, 19(8), 2001, pp. 2364-2364

Authors: Penson, RT Fuller, AF
Citation: Rt. Penson et Af. Fuller, Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva, J CL ONCOL, 19(8), 2001, pp. 2364-2365

Authors: Hoskins, PJ
Citation: Pj. Hoskins, Surgery in advanced epithelial ovarian cancer - In reply, J CL ONCOL, 19(8), 2001, pp. 2364-2364

Authors: Ernst, E
Citation: E. Ernst, Intangible risks of complementary and alternative medicine, J CL ONCOL, 19(8), 2001, pp. 2365-2366

Authors: Ganz, PA Litwin, MS
Citation: Pa. Ganz et Ms. Litwin, Prostate cancer: The price of early detection, J CL ONCOL, 19(6), 2001, pp. 1587-1588

Authors: Dorr, R Karanes, C Spier, C Grogan, T Greer, J Moore, J Weinberger, B Schiller, G Pearce, T Litchman, M Dalton, W Roe, D List, AF
Citation: R. Dorr et al., Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia, J CL ONCOL, 19(6), 2001, pp. 1589-1599

Authors: Thiede, C Wundisch, T Alpen, B Neubauer, B Morgner, A Schmitz, M Ehninger, G Stolte, M Bayerdorffer, E Neubauer, A
Citation: C. Thiede et al., Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma, J CL ONCOL, 19(6), 2001, pp. 1600-1609

Authors: Swerdlow, AJ Schoemaker, MJ Allerton, R Horwich, A Barber, JA Cunningham, D Lister, TA Rohatiner, AZS Hudson, GV Williams, MV Linch, DC
Citation: Aj. Swerdlow et al., Lung cancer after Hodgkin's disease: A nested case-control study of the relation to treatment, J CL ONCOL, 19(6), 2001, pp. 1610-1618

Authors: Madalinska, JB Essink-Bot, ML de Koning, HJ Kirkels, WJ van der Maas, PJ Schroder, FH
Citation: Jb. Madalinska et al., Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer, J CL ONCOL, 19(6), 2001, pp. 1619-1628

Authors: de Wit, R Roberts, JT Wilkinson, PM de Mulder, PHM Mead, GM Fossa, SD Cook, P de Prijck, L Stenning, S Collette, L
Citation: R. De Wit et al., Equivalence of three or four cycles of bleomycin, etoposide, and cisplatinchemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medicalresearch council, J CL ONCOL, 19(6), 2001, pp. 1629-1640
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>